Aastrom Biosciences, Inc.
Biotech company concludes stock agreement
Published in Healthcare Mergers, Acquisitions and Ventures Week, February 5th, 2005
In this final tranche, Fusion bought 4.8 million shares of Aastrom's common stock for gross proceeds of $12 million at an average price of $2.50 per share, a premium to the closing price of $2.38 per share.
This completes the $24 million common stock purchase agreement between Aastrom and Fusion.
Our issuance of these shares to Fusion was not registered under the Securities Act of 1933. The resale by Fusion of the shares...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Mergers, Acquisitions and Ventures Week
More Articles from Healthcare Mergers, Acquisitions and Ventures Week
- AMS Health Sciences, Inc.
Infomercial launched to test market weight loss product - AUXILIO, Inc.
Image management services provider names chief financial officer - Abiomed, Inc.
Medical device maker provides third quarter financial update - Advanced BioNutrition Corp.
Functional nutrition company secures $7.5M in private financing - Affymetrix, Inc.
Microarray maker expects record fourth quarter revenue of more than $100M - Albemarle Corporation
Chemical maker announces common stock and debt offerings - More from this issue of Healthcare Mergers, Acquisitions and Ventures Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
